![The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy](https://c8.alamy.com/zooms/6/0ea4228a6a0945a9b37c7c6f2d2c5f36/2c2h2np.jpg)
The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy
![The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy](https://c8.alamy.com/comp/2C2H2HC/the-trimbow-inhaler-to-ease-the-effects-of-chronic-obstructive-pulmonary-disease-by-combining-corticosteroid-beclometasone-beta2-agonist-formoterol-2C2H2HC.jpg)
The Trimbow inhaler to ease the effects of chronic obstructive pulmonary disease by combining corticosteroid beclometasone, beta2-agonist formoterol Stock Photo - Alamy
![Frontiers | Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality? Frontiers | Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?](https://www.frontiersin.org/files/Articles/816843/fmed-09-816843-HTML/image_m/fmed-09-816843-g001.jpg)
Frontiers | Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?
![Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA/LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA/LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X](https://pbs.twimg.com/media/DPVNbspWkAErhbn.jpg)
Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA/LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X
![TRICOP – A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD - ScienceDirect TRICOP – A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0954611121001049-gr4.jpg)
TRICOP – A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD - ScienceDirect
![Trimbow 87micrograms/dose / 5micrograms/dose / 9micrograms/dose inhaler (Chiesi Ltd) 120 dose - RightBreathe Trimbow 87micrograms/dose / 5micrograms/dose / 9micrograms/dose inhaler (Chiesi Ltd) 120 dose - RightBreathe](https://www.rightbreathe.com/wp-content/uploads/2017/09/Trimbow-Image27737.pdf.jpg)